A clinical deep-dive into how BPC-157 pentadecapeptide may affect sexual function, covering the proposed mechanisms, animal-model data, the absence of human RCTs, dosing considerations, and what compounding regulations mean for patients today.
An independent clinical assessment of Alloy Women's menopause HRT platform: prescribing model, compounded hormone safety, regulatory standing, cost, and how it compares to alternatives.
An evidence-based breakdown of who benefits most from Amble's cash telehealth GLP-1 program, including clinical eligibility criteria, realistic weight-loss expectations, and how it compares to alternatives.
An evidence-based assessment of Care/of's safety record, regulatory standing, third-party testing practices, and how it compares to alternatives. prepared by the HealthRX.com Editorial Team.
Done ADHD costs $199 the first month, then $79-$99 monthly, plus $30-$300+ for medication. Total annual cost can top $1,500. See the full breakdown.
An independent review of Help Pharmacy's compounding model, GLP-1 and HRT products, regulatory standing, pricing, and how it compares with alternatives. prepared by the HealthRX.com Editorial Team.
A detailed breakdown of Found's membership fees, GLP-1 drug costs, and total out-of-pocket expenses compared with alternatives. prepared by the HealthRX.com Editorial Team.
A breakdown of how Function Health works, what it prescribes, how much it costs, and how it compares to alternatives, with an evidence-boundary review of the lab panels it uses.
A clinical review of who should not use Happy Head compounded hair loss treatments, covering contraindications, safety concerns, and which patients are poor candidates for compounded minoxidil and finasteride.
Bupa doesn't cover Juniper's GLP-1 program; monthly fees run AU$99-599 depending on medication tier, plus dietitian coaching, with no lock-in contract.
An evidence-based breakdown of the Juniper ideal patient profile, covering eligibility criteria, what the program prescribes, how it compares to alternatives, and what real clinical outcomes look like for women pursuing GLP-1-assisted weight management.
An evidence-based assessment of Life Extension's safety record, regulatory posture, third-party testing practices, and how its supplement and Rx offerings compare against available clinical evidence.
An evidence-based comparison of Marek Health and its top alternatives for TRT, peptides, HRT, and lab optimization. prepared by the HealthRX.com Editorial Team.
A clinical breakdown of Mochi Health alternatives for GLP-1 weight loss, TRT, HRT, and metabolic care. Compare cost, prescribing model, and outcomes so you can choose the right telehealth platform.
A clinical breakdown of Mochi Health's intake and prescription process for GLP-1 weight loss therapy, including costs, legitimacy, what drugs are prescribed, and how it stacks up against alternatives.
An independent clinical review of Momentous performance supplements, covering creatine evidence, protein quality, third-party testing gaps, pricing, and how the brand compares to pharmaceutical-grade alternatives.
An evidence-based look at the ideal user profile for Momentous performance supplements, including creatine, protein, and sleep formulas. prepared by the HealthRX.com Editorial Team.
An independent, evidence-based assessment of Olipop's safety profile, ingredient regulation, gut-health claims, and how it compares to alternatives. prepared by the HealthRX.com Editorial Team.
A breakdown of the best PlushCare alternatives for GLP-1 weight loss, primary care, mental health, and more, with real costs, prescribing data, and head-to-head comparisons.
A clinical breakdown of which patients should avoid Ro's telehealth platform, covering GLP-1, ED, hair loss, and mental health services, with independent analysis of legitimacy, complaints, and safety concerns.
Seed's DS-01 has only one published RCT on the full formula. See what the research actually shows on strains, dosing, and price before you subscribe.
An evidence-based look at Shapiro MD's direct-to-consumer hair loss model, what it prescribes, how it compares to alternatives, and whether the clinical evidence supports its claims.
A critical, evidence-based review of Strut Health's compounding telehealth model, what it prescribes for hair loss, skin, and sexual health, how it compares to alternatives, and what real costs look like.
An evidence-based review of Superpower's safety posture, regulatory standing, prescribing practices for GLP-1s and peptides, and how it compares to competing telehealth platforms. Written and prepared by the HealthRX.com Editorial Team.
An independent analysis of Thorne's Better Business Bureau rating, consumer complaint patterns, FDA warning letters, and third-party verification status to help you decide whether this supplement brand is trustworthy.
An independent clinical analysis of Truepill's B2B pharmacy infrastructure model and the best alternatives for GLP-1, TRT, HRT, peptide, and direct-to-patient telehealth use cases in 2025.
A detailed, independent look at AG1 (Athletic Greens) pricing history, subscription cost changes, legitimacy, and complaints, with primary sources and clinical context.
A critical, evidence-based review of Thrive Causemetics ingredients, safety signals, BBB complaints, FDA status, and which patient profiles should avoid the brand's products.
Not every patient is a good candidate for Viome's microbiome testing and personalized supplements. Learn which profiles should skip it, what the complaints reveal, and whether Viome is legit by clinical standards.
A clinically grounded breakdown of the Winona ideal patient profile, what it prescribes, how it compares to alternatives, and what the evidence says about telehealth menopause HRT.
A clinical review of Women's International Pharmacy's prescription intake process, compounded bioidentical hormone therapy offerings, costs, legitimacy, and how it stacks up against alternatives.
A breakdown of the best ZOE alternatives for personalized nutrition, CGM monitoring, gut microbiome testing, and metabolic health, with cited evidence and real cost comparisons.
An evidence-based comparison of compounded bremelanotide and FDA-approved Vyleesi for HSDD, covering pharmacology, safety, efficacy data from RECONNECT, dosing, and how to choose between options.
Complete clinical guide to bremelanotide (Vyleesi) dosing for young adults aged 18 to 29, including injection technique, timing, side-effect management, and RECONNECT trial data.
A guide to bremelanotide (Vyleesi) safety in women ages 18 to 29, covering nausea rates, blood pressure effects, contraceptive interactions, fertility considerations, and dosing from the RECONNECT trials.
Lisinopril is not a diuretic. It is an ACE inhibitor that lowers blood pressure by blocking angiotensin II. Learn how it differs from diuretics, when the two drug classes are combined, and what clinical guidelines say about each.
Beta blockers lower heart rate by design, but bradycardia becomes a clinical problem when the rate drops too far. Learn the thresholds, drug interactions, and management steps backed by trial data.
A guide to cardiometabolic conditions in pregnancy, covering gestational diabetes management, GLP-1 receptor agonist safety, glucose targets, and long-term cardiovascular risk after delivery.
A guide to spironolactone for blood pressure control, including how it compares with atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a full cardiometabolic treatment plan.
Compare statin intensity without assuming exact dose equivalence, and learn why interactions, kidney function, and individual response matter.
A physician-level review of tadalafil's effects on bone density and bone metabolism, covering PDE5 inhibition mechanisms, preclinical and clinical evidence, fracture risk data, and practical guidance for men on long-term Cialis therapy.
A clinician-level review of tadalafil's effects on cerebral blood flow, cognition, and neurological outcomes, with primary-literature citations and dosing context.
An evidence-based breakdown of every clinically significant drug-drug interaction for tadalafil (Cialis), including nitrates, alpha-blockers, CYP3A4 inhibitors, antihypertensives, and more. Includes mechanisms, clinical thresholds, and management guidance.
A guide to tadalafil's documented effects on hair and skin, covering PDE5 inhibitor mechanisms, dermatologic adverse events, and what the primary literature says.
A deep dive into how tadalafil is absorbed, metabolized, and cleared, plus what the clinical evidence says about its effects on thermogenesis and energy expenditure in men.
A clinician-level guide to tadalafil pharmacokinetics, dosing adjustments, drug interactions, and safety monitoring for patients who have undergone bariatric surgery, including Roux-en-Y gastric bypass and sleeve gastrectomy.
A deep dive into tadalafil safety during pregnancy and breastfeeding, covering FDA classification, animal data, placental transfer, PDE5 physiology in pregnancy, and clinical decision-making for women who take Cialis for PAH or other indications.
Evidence-based guide to tadalafil (Cialis) dosing adjustments in chronic kidney disease and dialysis, including mechanism of action, pharmacokinetics, and safety data with PubMed-cited references.
No food, alcohol or supplement interaction for CJC-1295 has been established. The human studies measured growth hormone, IGF-I and side effects.
CJC-1295 has no established new formulation. Three healthy-volunteer studies exist, the DAC trials stopped in 2006, and FDA lists no approved product.
A physician-level review of how CJC-1295 (modified GRF) affects liver enzymes, IGF-1 hepatic signaling, and clinical safety markers, with primary-literature citations.
Evidence-based dosing guide for CJC-1295 (modified GRF) in adults aged 50 to 64, covering starting doses, titration, IGF-1 monitoring, and age-specific safety considerations including cardiovascular and polypharmacy risks.
No study or regulator guidance sets a CJC-1295 hold time before surgery. Studies of the DAC form report a half-life of 5.8 to 8.1 days.
A prescriber-level guide to managing metformin adverse events: GI tolerability, lactic acidosis risk stratification, B12 depletion monitoring, renal dose adjustment, and drug interactions, with citations to primary guidelines and trials.
A clinician-level review of biguanide drug-drug interactions, covering metformin's DDI mechanisms, contraindications, iodinated contrast protocols, and dosing adjustments with pharmacokinetic data and guideline citations.
A prescriber-level guide to choosing between alendronate, risedronate, ibandronate, zoledronic acid, and pamidronate based on indication, renal function, adherence profile, and fracture-reduction evidence.
A clinical-level review of copper peptide pharmacology, adverse-event profiles, and management protocols for prescribers and dispensers. Covers GHK-Cu, dosing thresholds, skin and systemic reactions, and monitoring frameworks.
A prescriber-level guide to DPP-4 inhibitor pharmacology, place in T2D therapy, formulary strategy, prior-authorization requirements, and denial appeals, with trial data, dosing tables, and step-edit navigation.
Complete DDI table, prescribing guide, and clinical pharmacology review for GLP-1/GIP/glucagon triple agonists including retatrutide. Written at MD/PharmD level with primary-source citations.
A clinical guide to selecting among GLP-1/GIP/glucagon triple agonists, including retatrutide and emerging agents, with dosing, trial data, and patient-selection frameworks for prescribers and dispensers.